Literature DB >> 27282912

Synthesis of GPR40 targeting 3 H- and 18 F-probes towards selective beta cell imaging.

Romain Bertrand1,2, Isabel Hamp1, Mark Brönstrup1,3, Remo Weck4, Mario Lukacevic5, Andras Polyak5, Tobias L Ross5, Martin Gotthardt2, Oliver Plettenburg1,6,7, Volker Derdau4.   

Abstract

Diabetes affects an increasing number of patients worldwide and is responsible for a significant rise in healthcare expenses. Imaging of β-cells in vivo is expected to contribute to an improved understanding of the underlying pathophysiology, improved diagnosis, and development of new treatment options for diabetes. Here, we describe the first radiosyntheses of [3 H]-TAK875 and [18 F]-TAK875 derivatives to be used as β-cell imaging probes addressing the free fatty acid receptor 1 (FFAR1/GPR40). The fluorine-labeled derivative showed similar agonistic activity as TAK875 in a functional assay. The radiosynthesis of the 18 F-labelled tracer 2a was achieved with 16.7 ± 5.7% radiochemical yield in a total synthesis time of 60-70 min.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  GPR40; beta cell imaging; fluorine-18; tritium

Mesh:

Substances:

Year:  2016        PMID: 27282912     DOI: 10.1002/jlcr.3412

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN: 0362-4803            Impact factor:   1.921


  3 in total

Review 1.  Molecular imaging of β-cells: diabetes and beyond.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quan-Yong Luo; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

2.  GPR40 is a low-affinity epoxyeicosatrienoic acid receptor in vascular cells.

Authors:  Sang-Kyu Park; Anja Herrnreiter; Sandra L Pfister; Kathryn M Gauthier; Benjamin A Falck; John R Falck; William B Campbell
Journal:  J Biol Chem       Date:  2018-05-18       Impact factor: 5.157

3.  Toward molecular imaging of the free fatty acid receptor 1.

Authors:  Ewa Hellström-Lindahl; Ola Åberg; Cecilia Ericsson; Gavin O'Mahony; Peter Johnström; Stanko Skrtic; Olof Eriksson
Journal:  Acta Diabetol       Date:  2017-04-13       Impact factor: 4.280

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.